5HT
vs
D
DAX Index
5HT
Over the past 12 months, 5HT has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +22% growth.
Stocks Performance
5HT vs DAX Index
Performance Gap
5HT vs DAX Index
Performance By Year
5HT vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Harpoon Therapeutics Inc
Glance View
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. The company is headquartered in South San Francisco, California and currently employs 99 full-time employees. The company went IPO on 2019-02-08. The firm is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The company is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. The company has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.
